A cancer 'moonshot'
A new institute is strengthening Johns Hopkins' world-class program in cancer immunology, an example of how Hopkins embraces collaboration across disciplines to promote discovery
This is the first in a series of articles highlighting Johns Hopkins University's goals articulated in the Ten by Twenty vision plan, 10 goals to be reached by the year 2020.
Immunotherapy—redirecting patients' highly individual immune systems to target, detect, and destroy cancer cells—is one of the most promising avenues of cancer research today. Johns Hopkins is on the cutting edge of this rapidly advancing approach to treatment and potentially a cure, thanks to the pathbreaking work being done at the Bloomberg–Kimmel Institute for Cancer Immunotherapy.
Launched in March 2016 with $50 million gifts from Michael R. Bloomberg and Sidney Kimmel, along with an additional $25 million contributed by other supporters, the institute further strengthens Johns Hopkins' world-class program in cancer immunology, uniting the Johns Hopkins Kimmel Cancer Center experts with the immunology, genetics, microbiology, and biomedical engineering experts throughout Johns Hopkins in a concentrated effort involving more than 100 scientists and clinicians.
As then-Vice President Joe Biden said at the launch of the institute, "I'm convinced that not only will we save millions of lives, we will reinstill in the American public the notion that anything is possible."
Tomorrow's most pressing questions will not be confined to silos, and neither will be the solutions. From its earliest days, Johns Hopkins has embraced robust collaboration across world-class disciplines, understanding that both our intellectual curiosity and our drive to advance humanity are better served if we work together.
The university will build its future on strong and vibrant disciplines. At the same time, we will seek to remove the barriers that stand in the way of interdisciplinary scholarship and research—fostering interactions across the university that respect the discipline of the disciplines while promoting the cross-pollination of ideas that will catalyze a new generation of discovery.
The creation of the Bloomberg–Kimmel Institute for Cancer Immunotherapy aligns with Goal No. 3 of the Ten by Twenty, to enhance the impact of Johns Hopkins Medicine, the Bloomberg School of Public Health, and the School of Nursing as the world's pre-eminent academic health sciences enterprise by deepening collaboration among these entities and with disciplines in other parts of the university and across the globe.